التفاصيل البيبلوغرافية
| العنوان: |
Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction |
| المؤلفون: |
Levine, Andrea R, Simon, Marc A, Gladwin, Mark T |
| المصدر: |
Trends in Cardiovascular Medicine, vol 29, iss 4 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2019 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Heart Disease, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Animals, Arterial Pressure, Heart Failure, Humans, Hypertension, Pulmonary, Prognosis, Pulmonary Artery, Pulmonary Circulation, Risk Factors, Stroke Volume, Vascular Remodeling, Vascular Resistance, Ventricular Function, Left, PH-HFpEF, HFpEF, Pulmonary Hypertension, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology |
| جغرافية الموضوع: |
207 - 217 |
| الوصف: |
Heart failure with preserved ejection fraction (HFpEF) is defined as clinical features of heart failure, ideally with biomarker evidence such as elevated plasma natriuretic peptide levels, in the setting of an ejection fraction (EF) greater than 50% and imaging evidence of diastolic left ventricular dysfunction [1,2]. In the absence of cardiac imaging or invasive hemodynamics, this is a clinical syndrome that is often indistinguishable from heart failure with reduced ejection fraction (HFrEF). HFpEF and HFrEF present with a cadre of comparable signs and symptoms including jugular venous distention, pulmonary rales on auscultation, breathlessness, orthopnea, exercise intolerance, exertional dyspnea, fatigue and peripheral edema. HFpEF accounts for at least half of all diagnoses of heart failure [1,2]. Pulmonary hypertension (PH) is a common complication of HFpEF that is linked to worse disease morbidity and mortality. In fact, mortality has been linked to increases in the intrinsic pulmonary vascular resistance in the setting of increased left ventricular end diastolic pressure, characterized hemodynamically by rises in the transpulmonary pressure gradient, pulmonary vascular resistance or diastolic pressure gradient. Despite being the most common form of PH, there are no approved therapies for the treatment of PH secondary to HFpEF. This review will summarize the hemodynamic classifications of PH in the setting of HFpEF, mechanisms of disease, the potential contribution of pulmonary vascular disease to poor outcomes in patients with HFpEF, and new approaches to therapy. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt0f89x6b8; https://escholarship.org/uc/item/0f89x6b8Test |
| الإتاحة: |
https://escholarship.org/uc/item/0f89x6b8Test |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.FAE1B39C |
| قاعدة البيانات: |
BASE |
